NICE-话题@MedSci

#NICE#

226篇内容 | 5115人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1289080, encodeId=8349128908097, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, objectTitle=英国NICE推荐TRK抑制剂VITRAKVI（larotrectinib），用于NTRK基因融合阳性的实体瘤, objectType=article, longId=192797, objectId=6bd8192e9745, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6bd8192e9745, replyNumber=0, likeNumber=0, createdTime=2020-04-24, rootId=0, userName=fusion, userId=743b215, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6bd8192e9745, moduleTitle=英国NICE推荐TRK抑制剂VITRAKVI（larotrectinib），用于NTRK基因融合阳性的实体瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6bd8192e9745)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1289079, encodeId=04af12890e988, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, objectTitle=英国NICE发布了新型冠状病毒COVID-19管理指南：针对囊性纤维化、慢性阻塞性肺病和需要使用会影响免疫系统药物的皮肤病患者, objectType=article, longId=192006, objectId=57b7192006f6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=57b7192006f6, replyNumber=0, likeNumber=57, createdTime=2020-04-12, rootId=0, userName=fusion, userId=743b215, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=57b7192006f6, moduleTitle=英国NICE发布了新型冠状病毒COVID-19管理指南：针对囊性纤维化、慢性阻塞性肺病和需要使用会影响免疫系统药物的皮肤病患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=57b7192006f6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1289078, encodeId=e8c612890e88b, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, objectTitle=英国NICE更新了针对患有基础疾病的新型冠状病毒感染者的管理指南, objectType=article, longId=191819, objectId=fd5f19181982, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fd5f19181982, replyNumber=0, likeNumber=62, createdTime=2020-04-10, rootId=0, userName=fusion, userId=743b215, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fd5f19181982, moduleTitle=英国NICE更新了针对患有基础疾病的新型冠状病毒感染者的管理指南, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fd5f19181982)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1289077, encodeId=1f1b12890e723, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, objectTitle=英国NICE批准将抗CGRP单抗Ajovy用于预防偏头痛，患者只需每月或每季度自行注射一次, objectType=article, longId=190015, objectId=4b4d190015f6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4b4d190015f6, replyNumber=0, likeNumber=61, createdTime=2020-03-16, rootId=0, userName=fusion, userId=743b215, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4b4d190015f6, moduleTitle=英国NICE批准将抗CGRP单抗Ajovy用于预防偏头痛，患者只需每月或每季度自行注射一次, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4b4d190015f6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1289076, encodeId=f82212890e6c2, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, objectTitle=NICE推荐将血小板生成素受体激动剂Doptelet用于肝病手术前使用, objectType=article, longId=189454, objectId=0976189454ff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0976189454ff, replyNumber=0, likeNumber=76, createdTime=2020-03-07, rootId=0, userName=fusion, userId=743b215, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0976189454ff, moduleTitle=NICE推荐将血小板生成素受体激动剂Doptelet用于肝病手术前使用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0976189454ff)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1289075, encodeId=b32b12890e5f8, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, objectTitle=2020 NICE指南：脓疱病抗菌药物处方（NG.153）, objectType=article, longId=189286, objectId=996a189286eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=996a189286eb, replyNumber=0, likeNumber=34, createdTime=2020-03-05, rootId=0, userName=fusion, userId=743b215, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=996a189286eb, moduleTitle=2020 NICE指南：脓疱病抗菌药物处方（NG.153）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=996a189286eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1289074, encodeId=224c12890e482, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, objectTitle=英国NICE推荐将来那度胺与利妥昔单抗联合用于治疗滤泡性淋巴瘤, objectType=article, longId=189157, objectId=3e3b18915ec7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3e3b18915ec7, replyNumber=0, likeNumber=65, createdTime=2020-03-04, rootId=0, userName=fusion, userId=743b215, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3e3b18915ec7, moduleTitle=英国NICE推荐将来那度胺与利妥昔单抗联合用于治疗滤泡性淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3e3b18915ec7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1289073, encodeId=579612890e368, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, objectTitle=2020 NICE指南：结直肠癌（NG.151）, objectType=article, longId=187750, objectId=5ff718e75043, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5ff718e75043, replyNumber=0, likeNumber=30, createdTime=2020-02-11, rootId=0, userName=fusion, userId=743b215, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5ff718e75043, moduleTitle=2020 NICE指南：结直肠癌（NG.151）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5ff718e75043)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1289072, encodeId=830612890e2f3, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, objectTitle=被英国NICE拒绝后，强生的IL-23/IL-12单抗Stelara获得欧盟扩展适应症治疗儿童牛皮癣, objectType=article, longId=187183, objectId=a1b618e18333, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a1b618e18333, replyNumber=0, likeNumber=70, createdTime=2020-02-03, rootId=0, userName=fusion, userId=743b215, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a1b618e18333, moduleTitle=被英国NICE拒绝后，强生的IL-23/IL-12单抗Stelara获得欧盟扩展适应症治疗儿童牛皮癣, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a1b618e18333)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1289071, encodeId=f3fd12890e1f5, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, objectTitle=辉瑞的CDK4/6抑制剂Ibrance，获英国NICE批准治疗乳腺癌, objectType=article, longId=186505, objectId=22ce186505e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=22ce186505e0, replyNumber=0, likeNumber=77, createdTime=2020-01-20, rootId=0, userName=fusion, userId=743b215, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=22ce186505e0, moduleTitle=辉瑞的CDK4/6抑制剂Ibrance，获英国NICE批准治疗乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=22ce186505e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1289070, encodeId=23b212890e0ba, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, objectTitle=英国NICE批准将PARP抑制剂Lynparza，用于BRCA1或BRCA2突变的铂敏感型卵巢癌、输卵管癌或腹膜癌复发患者, objectType=article, longId=186454, objectId=6fbf186454dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6fbf186454dd, replyNumber=0, likeNumber=127, createdTime=2020-01-19, rootId=0, userName=fusion, userId=743b215, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6fbf186454dd, moduleTitle=英国NICE批准将PARP抑制剂Lynparza，用于BRCA1或BRCA2突变的铂敏感型卵巢癌、输卵管癌或腹膜癌复发患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6fbf186454dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1289069, encodeId=a13f128906981, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, objectTitle=拜耳的TRK抑制剂Vitrakvi被英国NICE认为"价格不合算"，遭拒绝使用, objectType=article, longId=186452, objectId=4bfd18645232, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4bfd18645232, replyNumber=0, likeNumber=63, createdTime=2020-01-19, rootId=0, userName=fusion, userId=743b215, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4bfd18645232, moduleTitle=拜耳的TRK抑制剂Vitrakvi被英国NICE认为"价格不合算"，遭拒绝使用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4bfd18645232)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1289068, encodeId=be17128906858, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, objectTitle=英国NICE拒绝将PD-1单抗Keytruda，用于转移或复发的头颈部鳞状细胞癌, objectType=article, longId=186378, objectId=17ce1863e8ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=17ce1863e8ed, replyNumber=0, likeNumber=86, createdTime=2020-01-18, rootId=0, userName=fusion, userId=743b215, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=17ce1863e8ed, moduleTitle=英国NICE拒绝将PD-1单抗Keytruda，用于转移或复发的头颈部鳞状细胞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=17ce1863e8ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1289067, encodeId=4217128906e1b, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, objectTitle=因价格问题，英国NICE拒绝Akcea的反义寡链核苷酸药物Waylivra上市, objectType=article, longId=185670, objectId=0d8d1856e076, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0d8d1856e076, replyNumber=0, likeNumber=113, createdTime=2020-01-05, rootId=0, userName=fusion, userId=743b215, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0d8d1856e076, moduleTitle=因价格问题，英国NICE拒绝Akcea的反义寡链核苷酸药物Waylivra上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0d8d1856e076)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1289066, encodeId=cf601289066d9, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, objectTitle=因价格问题，NICE拒绝将罗氏的PD-L1单抗Tecentriq联合化疗用于广泛期小细胞肺癌, objectType=article, longId=185527, objectId=8ca718552e25, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8ca718552e25, replyNumber=0, likeNumber=86, createdTime=2020-01-03, rootId=0, userName=fusion, userId=743b215, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8ca718552e25, moduleTitle=因价格问题，NICE拒绝将罗氏的PD-L1单抗Tecentriq联合化疗用于广泛期小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8ca718552e25)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1289065, encodeId=cb5d12890655d, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, objectTitle=NICE批准PARP抑制剂Lynparza扩展用于晚期卵巢癌、输卵管癌和腹膜癌的维持治疗, objectType=article, longId=184088, objectId=1ff918408873, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1ff918408873, replyNumber=0, likeNumber=64, createdTime=2019-12-05, rootId=0, userName=fusion, userId=743b215, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1ff918408873, moduleTitle=NICE批准PARP抑制剂Lynparza扩展用于晚期卵巢癌、输卵管癌和腹膜癌的维持治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1ff918408873)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1289064, encodeId=4f72128906449, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, objectTitle=英国NICE推荐将辉瑞的细胞周期蛋白依赖性激酶抑制剂Ibrance用于治疗晚期或转移性乳腺癌, objectType=article, longId=184022, objectId=bfe4184022fb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bfe4184022fb, replyNumber=0, likeNumber=134, createdTime=2019-12-04, rootId=0, userName=fusion, userId=743b215, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bfe4184022fb, moduleTitle=英国NICE推荐将辉瑞的细胞周期蛋白依赖性激酶抑制剂Ibrance用于治疗晚期或转移性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bfe4184022fb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1289063, encodeId=39e8128906303, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, objectTitle=NICE推荐将Elmiron（戊糖多硫酸钠）用于治疗膀胱疼痛综合症, objectType=article, longId=183121, objectId=a22e183121da, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a22e183121da, replyNumber=0, likeNumber=64, createdTime=2019-11-19, rootId=0, userName=fusion, userId=743b215, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a22e183121da, moduleTitle=NICE推荐将Elmiron（戊糖多硫酸钠）用于治疗膀胱疼痛综合症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a22e183121da)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1289062, encodeId=9aeb128906208, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, objectTitle=英国NICE更新指南，推荐将拜尔的大麻二酚药物Sativex用于治疗多发性硬化症患者的痉挛, objectType=article, longId=183118, objectId=b4f118311887, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b4f118311887, replyNumber=0, likeNumber=100, createdTime=2019-11-19, rootId=0, userName=fusion, userId=743b215, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b4f118311887, moduleTitle=英国NICE更新指南，推荐将拜尔的大麻二酚药物Sativex用于治疗多发性硬化症患者的痉挛, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b4f118311887)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1289061, encodeId=5e361289061c2, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, objectTitle=英国NICE批准拜耳的抗凝剂Xarelto用于预防动脉粥样硬化血栓, objectType=article, longId=181602, objectId=11fc181602ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=11fc181602ea, replyNumber=0, likeNumber=73, createdTime=2019-10-21, rootId=0, userName=fusion, userId=743b215, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=11fc181602ea, moduleTitle=英国NICE批准拜耳的抗凝剂Xarelto用于预防动脉粥样硬化血栓, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=11fc181602ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

NICE

2020-05-29

fusion (审核中...)

前往app查看评论内容

#NICE#

英国NICE推荐TRK抑制剂VITRAKVI（larotrectinib），用于NTRK基因融合阳性的实体瘤

2020-04-24

fusion (审核中...)

前往app查看评论内容

#NICE#

英国NICE发布了新型冠状病毒COVID-19管理指南：针对囊性纤维化、慢性阻塞性肺病和需要使用会影响免疫系统药物的皮肤病患者

2020-04-12

fusion (审核中...)

前往app查看评论内容

#NICE#

英国NICE更新了针对患有基础疾病的新型冠状病毒感染者的管理指南

2020-04-10

fusion (审核中...)

前往app查看评论内容

#NICE#

英国NICE批准将抗CGRP单抗Ajovy用于预防偏头痛，患者只需每月或每季度自行注射一次

2020-03-16

fusion (审核中...)

前往app查看评论内容

#NICE#

NICE推荐将血小板生成素受体激动剂Doptelet用于肝病手术前使用

2020-03-07

fusion (审核中...)

前往app查看评论内容

#NICE#

2020 NICE指南：脓疱病抗菌药物处方（NG.153）

2020-03-05

fusion (审核中...)

前往app查看评论内容

#NICE#

英国NICE推荐将来那度胺与利妥昔单抗联合用于治疗滤泡性淋巴瘤

2020-03-04

fusion (审核中...)

前往app查看评论内容

#NICE#

2020 NICE指南：结直肠癌（NG.151）

2020-02-11

fusion (审核中...)

前往app查看评论内容

#NICE#

被英国NICE拒绝后，强生的IL-23/IL-12单抗Stelara获得欧盟扩展适应症治疗儿童牛皮癣

2020-02-03

fusion (审核中...)

前往app查看评论内容

#NICE#

辉瑞的CDK4/6抑制剂Ibrance，获英国NICE批准治疗乳腺癌

2020-01-20

fusion (审核中...)

前往app查看评论内容

#NICE#

英国NICE批准将PARP抑制剂Lynparza，用于BRCA1或BRCA2突变的铂敏感型卵巢癌、输卵管癌或腹膜癌复发患者

2020-01-19

fusion (审核中...)

前往app查看评论内容

#NICE#

拜耳的TRK抑制剂Vitrakvi被英国NICE认为"价格不合算"，遭拒绝使用

2020-01-19

fusion (审核中...)

前往app查看评论内容

#NICE#

英国NICE拒绝将PD-1单抗Keytruda，用于转移或复发的头颈部鳞状细胞癌

2020-01-18

fusion (审核中...)

前往app查看评论内容

#NICE#

因价格问题，英国NICE拒绝Akcea的反义寡链核苷酸药物Waylivra上市

2020-01-05

fusion (审核中...)

前往app查看评论内容

#NICE#

因价格问题，NICE拒绝将罗氏的PD-L1单抗Tecentriq联合化疗用于广泛期小细胞肺癌

2020-01-03

fusion (审核中...)

前往app查看评论内容

#NICE#

NICE批准PARP抑制剂Lynparza扩展用于晚期卵巢癌、输卵管癌和腹膜癌的维持治疗

2019-12-05

fusion (审核中...)

前往app查看评论内容

#NICE#

英国NICE推荐将辉瑞的细胞周期蛋白依赖性激酶抑制剂Ibrance用于治疗晚期或转移性乳腺癌

2019-12-04

fusion (审核中...)

前往app查看评论内容

#NICE#

NICE推荐将Elmiron（戊糖多硫酸钠）用于治疗膀胱疼痛综合症

2019-11-19

fusion (审核中...)

前往app查看评论内容

#NICE#

英国NICE更新指南，推荐将拜尔的大麻二酚药物Sativex用于治疗多发性硬化症患者的痉挛

2019-11-19

fusion (审核中...)

前往app查看评论内容

#NICE#

英国NICE批准拜耳的抗凝剂Xarelto用于预防动脉粥样硬化血栓

2019-10-21

科室
- - 订阅+
  - 更多科室
工具
服务